HC Wainwright & Co. Reiterates Buy on Verona Pharma, Maintains $32 Price Target

Verona Pharma plc Sponsored ADR -1.61%

Verona Pharma plc Sponsored ADR

VRNA

15.91

-1.61%

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Verona Pharma (NASDAQ: VRNA) with a Buy and maintains $32 price target.
Every question you ask will be answered
Scan the QR code to contact us
whatsapp
Also you can contact us via